O'Brien Greene & Co. Inc Amgen Inc Transaction History

O'Brien Greene & Co. Inc

$305 Million
Q3 2024

A detailed history of O'Brien Greene & Co. Inc transactions in Amgen Inc stock. As of the latest transaction made, O'Brien Greene & Co. Inc holds 31,304 shares of AMGN stock, worth $9.01 Million. This represents 3.31% of its overall portfolio holdings.

Number of Shares

31,304

Previous 32,405 3.4%

Holding current value

$9.01 Million

Previous $10.1 Million 0.38%

% of portfolio

3.31%

Previous 3.34%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$309.38 - $337.38 $340,627 - $371,455	-1,101 Reduced 3.4%	31,304 $10.1 Million
Q2 2024 Aug 12, 2024	BUY	$262.75 - $319.31 $853,412 - $1.04 Million	3,248 Added 11.14%	32,405 $10.1 Million
Q1 2024 May 02, 2024	SELL	$268.87 - $324.56 $44,363 - $53,552	-165 Reduced 0.56%	29,157 $8.29 Million
Q4 2023 Feb 02, 2024	BUY	$255.7 - $288.46 $312,976 - $353,075	1,224 Added 4.36%	29,322 $8.45 Million
Q3 2023 Nov 08, 2023	BUY	$218.65 - $271.46 $190,006 - $235,898	869 Added 3.19%	28,098 $7.55 Million
Q2 2023 Aug 15, 2023	SELL	$214.27 - $253.37 $11.7 Million - $13.8 Million	-54,458 Reduced 66.67%	27,229 $6.05 Million
Q2 2023 Jul 20, 2023	BUY	$214.27 - $253.37 $11.6 Million - $13.7 Million	54,179 Added 196.96%	81,687 $18.1 Million
Q1 2023 May 03, 2023	BUY	$225.79 - $275.2 $126,442 - $154,112	560 Added 2.08%	27,508 $6.65 Million
Q4 2022 Feb 02, 2023	SELL	$229.03 - $291.01 $11.8 Million - $14.9 Million	-51,307 Reduced 65.56%	26,948 $7.08 Million
Q3 2022 Nov 09, 2022	BUY	$224.46 - $253.15 $11.9 Million - $13.4 Million	52,903 Added 208.67%	78,255 $17.6 Million
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $70,366 - $78,305	305 Added 1.22%	25,352 $6.17 Million
Q1 2022 May 18, 2022	BUY	$219.27 - $242.57 $21,269 - $23,529	97 Added 0.39%	25,047 $6.06 Million
Q4 2021 Feb 08, 2022	SELL	$198.88 - $227.6 $2,585 - $2,958	-13 Reduced 0.05%	24,950 $5.61 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $39,057 - $45,760	184 Added 0.74%	24,963 $5.31 Million
Q2 2021 Aug 09, 2021	BUY	$233.58 - $259.14 $124,731 - $138,380	534 Added 2.2%	24,779 $6.04 Million
Q1 2021 May 12, 2021	SELL	$221.91 - $258.6 $12,205 - $14,223	-55 Reduced 0.23%	24,245 $6.03 Million
Q4 2020 Feb 04, 2021	BUY	$216.38 - $257.67 $28,129 - $33,497	130 Added 0.54%	24,300 $5.59 Million
Q3 2020 Nov 09, 2020	SELL	$234.65 - $260.95 $113,805 - $126,560	-485 Reduced 1.97%	24,170 $6.14 Million
Q2 2020 Aug 10, 2020	BUY	$197.81 - $242.74 $22,748 - $27,915	115 Added 0.47%	24,655 $5.82 Million
Q1 2020 May 07, 2020	SELL	$182.24 - $241.7 $29,158 - $38,672	-160 Reduced 0.65%	24,540 $4.98 Million
Q4 2019 Feb 05, 2020	SELL	$189.21 - $243.2 $89,874 - $115,520	-475 Reduced 1.89%	24,700 $5.96 Million
Q3 2019 Nov 07, 2019	BUY	$174.11 - $208.62 $64,420 - $77,189	370 Added 1.49%	25,175 $4.87 Million
Q2 2019 Aug 21, 2019	BUY	$166.7 - $195.41 $64,512 - $75,623	387 Added 1.58%	24,805 $4.57 Million
Q1 2019 Apr 29, 2019	BUY	$180.87 - $203.88 $103,095 - $116,211	570 Added 2.39%	24,418 $4.64 Million
Q4 2018 Feb 27, 2019	BUY	$178.4 - $208.25 $4.25 Million - $4.97 Million	23,848 New	23,848 $4.64 Million

Others Institutions Holding AMGN

# of Institutions

3,121

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $154B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Brien Greene & Co. Inc, based on Form 13F filings with the SEC.

News

Stay updated on O'Brien Greene & Co. Inc with notifications on news.

Account

O'Brien Greene & Co. Inc Amgen Inc Transaction History